← ANALYST RATINGS · TIPRANKS
Protara Therapeutics (TARA): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $24.00, the highest $27.00, the lowest $20.00. The average is +934.5% from the last price of $2.32.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | −13.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Sell | −13.8% | Downgrade | 17.10.26on TipRanks 07:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Sell | −13.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −13.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $2.50−16.7% | Hold | +7.8% | Reiterated | 02.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Hold | +7.8% | Reiterated | 02.10.26on TipRanks 04:05 | — | |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $27.00 | Buy | +1,063.8% | Reiterated | 21.09.26on TipRanks 13:55 | −2.7%next day +4.9% · 5 days −6.4% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $25.00 | Buy | +977.6% | Reiterated | 11.08.26on TipRanks Aug 12 01:15 | −4.5%next day −0.8% · 5 days +2.2% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $22.00 → $20.00−9.1% | Buy | +762.1% | Assigned | 11.08.26on TipRanks 19:05 | −0.8%next day +0.6% · 5 days +2.2% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Buy | — | Reiterated | 30.06.26on TipRanks Jul 1 08:36 | −9.0%next day +5.9% · 5 days +7.8% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $24.00 | Buy | +934.5% | Reiterated | 20.05.26on TipRanks May 21 01:45 | +8.7%next day +4.2% · 5 days −2.0% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $25.00 → $28.00+12.0% | Buy | +1,106.9% | Reiterated | 20.05.26on TipRanks 07:50 | +8.7%next day +4.2% · 5 days −2.0% | ↗ |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | $30.00 | Buy | +1,193.1% | Assigned | 20.05.26on TipRanks 06:45 | +8.7%next day +4.2% · 5 days −2.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Protara Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.00 at a price of $3.05 (+686.9%); now: $24.00 at $2.32 (+934.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 23 | 17 | 14 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.37 (from $-0.38 to $-0.34). Last quarter: $-0.36.
Best top-analyst consensus in the sector · Healthcare
About Protara Therapeutics
- CEO: Jesse Shefferman
- Employees: 46
- 345 Park Avenue South, New York City, NY, 10010, US
- www.protaratx.com
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Data from the stock’s TipRanks forecast page, read 13 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗